The ‘Pharmacoeconomic Evaluation Exemption System', which was first implemented in 2015, will be completely transformed in the new year.

In the future, the system will defer rather than exempt companies from submitting required data, increasing the possibility of drugs being evaluated after listing.

According to the industry on December 29th, the study on 'Preparation of a plan to improve the pharmacoeconomic evaluation data submission waiver system’ that was conducted as the Health Insurance Review and Assessment Service’s research service in February, has been completed.

The results of the study, which mention the need to redesign the system to defer data subm